Antegren Renamed, Approved; 'Blockbuster,' But How Soon?
By Randall Osborne
Monday, November 29, 2004
As many predicted, the FDA approved Biogen Idec Inc.'s multiple sclerosis drug Tysabri (formerly known as Antegren) as a combination and monotherapy for relapsing forms of the disease, but the company and partner Elan Corp. plc did not disclose pricing for the would-be blockbuster. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.